1.
Guminski A, Squittieri N, Lear JT. Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study. J of Skin [Internet]. 2020Sep.2 [cited 2022Aug.18];4(5):s67. Available from: https://www.jofskin.org/index.php/skin/article/view/1016